Fig. 7: CaMKII inhibitor-KN93 suppresses NEC severity.

A Representative Western blots showing the activation of CaMKII in Caco-2 cells transfected with sh-Ctrl or sh-Piezo1 exposure to LPS, or LPS with Yoda1 for 24 h. B Representative confocal images of the expression of p-CaMKII in the enteroids exposure to LPS or LPS with Yoda1. C Representative Western blots showing the activation of CaMKII and NFκB p65 in Caco-2 cells transfected with sh-Ctrl or sh-Piezo1 exposure to LPS, or LPS with Yoda1 or LPS with Yoda1 and KN-93 for 24 h. D Representative confocal images of the expression of p-CaMKII and p-NFκB p65 in the enteroids exposure to LPS or LPS with KN-93 and KN-92. E Representative images of H&E staining and IHC analysis of p-CaMKII and p-NFκB p65 levels in control samples and NEC samples from the KN-93 treatment experiments, Scale bar: 100 μm. F Quantification of the severity of NEC (n = 6 mice). G Fluorescence readings in plasma 4 h after gavage with FITC-dextran from the control samples and NEC samples from the KN-93 treatment experiments (n = 6 mice). P values were determined by unpaired two-tailed Student’s t test and Mann–Whitney U test, *P < 0.05; **P < 0.01; ***P < 0.001. Data are mean ± SEM.